.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cipla
Boehringer Ingelheim
Argus Health
Julphar
US Department of Justice
Citi
Daiichi Sankyo
Farmers Insurance
Covington

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,552,025

« Back to Dashboard

Which drugs does patent 8,552,025 protect, and when does it expire?


Patent 8,552,025 protects RELISTOR and is included in one NDA. There have been three Paragraph IV challenges on Relistor.

This patent has thirty-one patent family members in seventeen countries.

Summary for Patent: 8,552,025

Title:Stable methylnaltrexone preparation
Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
Inventor(s): Sanghvi; Suketu P. (Kendall Park, NJ), Boyd; Thomas A. (Grandview, NY)
Assignee: Progenics Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:12/639,862
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-001Apr 24, 2008RXYesYes► Subscribe► Subscribe► SubscribeY
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-003Sep 27, 2010RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,552,025

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,669,096Stable pharmaceutical formulations of methylnaltrexone► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,552,025

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2005134361► Subscribe
Portugal2368554► Subscribe
Portugal2368553► Subscribe
Portugal1615646► Subscribe
MexicoPA05010817► Subscribe
Japan2015147783► Subscribe
Japan2006522818► Subscribe
Japan5847643► Subscribe
Japan2012184240► Subscribe
Israel171228► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Citi
Queensland Health
Mallinckrodt
Medtronic
Fuji
Harvard Business School
Cipla
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot